Fig. 3.

Mogat1 ASO treatment lowers hepatic triglyceride during fasting. A: Mogat1 ASO treatment lowered hepatic triglyceride content during the fasted state compared with control ASO-treated mice. B, C: Total hepatic FFA and MAG were not different between ASO treatment groups as measured by LC/MS. D: Individual hepatic FFA species measured by LC/MS. E: Long-chain unsaturated MAG species were increased by fasting, but only increased by Mogat1 ASO in the fed state. Data are shown as box and whisker plots, *P < 0.05, where indicated, †P < 0.05 vs. fed state; n = 4–5.